Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Synthesis and Computational Evaluation of Substituted Analogues of 4-Sulfonamide Phenylhydrazones as Potential Anticancer Agents: Molecular Docking, Physicochemical Properties, ADME-Tox, and DFT Analysis.

Created on 21 Sep 2026

Authors

Darshan Upadhyay, Drashti Thanki, Chintan Somaiya

Published in

Current organic synthesis. Sep 16, 2026. Epub Sep 16, 2026.

Abstract

Ten derivatives of benzenesulfonamide (SBB-1 to 10) have been synthesized via the condensation of terminal ketone and aldehyde with aromatic 4-sulfonamide phenylhydrazine.
1H NMR, 13C NMR, IR, UV, and GC-MS were used to confirm the synthesized derivatives. The in vitro cytotoxicity of the synthesized sulfonamide derivatives SBB (1-10) was evaluated against the A549 human lung cancer cell line, using doxorubicin as the reference standard.
The compound SBB-5 (IC50 16.36 ± 0.41 μM) demonstrated high anticancer potency due to the presence of a hydroxy group on the phenyl ring against all tested strains.
The binding conformation of the most potent benzenesulfonamide (SBB-5) with the EGFR kinase (PDB code: 1M17) was ascertained by molecular docking studies. According to ADMET and DFT studies, the synthesized compounds showed favorable properties.
Promising compounds like SBB-2, SBB-3, SBB-5, SBB-6, and SBB-7 exhibit favourable physicochemical properties, high drug-likeness, solubility, and a non-toxic profile, making them strong candidates for further development of a promising drug.

PMID:
42764768
Bibliographic data and abstract were imported from PubMed on 21 Sep 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 7
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement